Five-star events at the UNESCO 🏛️ #Education #Sciences #Culture 🇺🇳 #InternetForTrust Conference! It was a great pleasure to engage in these thought-provoking discussions on how to build a more transparent and fairer digital environment through the enforcement of #AiEthics. Bravo to all the excellent speakers!

One of the topics at today's #KyotoSymposium: The role of #AI in medicine. "AI can support physicians in diagnosing melanoma or breast cancer. It can make predictions on drug-drug interactions. It can also help writing medical reports. The potential is huge." Krauthammer Lab

Highly interesting discussions around the future of law in the age of #AI and #digital platforms by the University of Zurich @uzh_en at the “Zurich-Tokyo Science Evening”. Guests from the Japanese #government, #academia, #business and #media joined. Krauthammer Lab Kerstin Noëlle Vokinger

Just in time for AACR, Cell's special issue on #Cancer: Untangling Complexity Together. Check out this amazing list of reviews and content (1/n) bit.ly/3KCnJCE #AACR23 #aacr2023 #CancerResearch Cell

New piece in Cell special issue on #Cancer: "Determinants of cancer drug pricing and how to overcome the cancer premium" cell.com/cell/fulltext/…

Cancer premium: Cancer drugs 3x more expensive than non-cancer drugs after adjusting for efficacy, prevalence, incidence & mortality. thelancet.com/journals/eclin… with miquel serra-burriel, Aaron Mitchell Funding: Swiss National Science Foundation Covered by El Pais shorturl.at/cpLT0 & Swiss national news:

New piece: Drugs increasingly approved for many indications. Findings indicate substantially lower R&D costs for supplemental indications compared to first indications. More public data necessary to validate findings. with Olivier Wouters LSE Health Policy jamanetwork.com/journals/jama-…

New study The Lancet Digital Health: Analysis of 510(k) predicate network of AI medical devices. Tasks of AI medical devices change over time and may raise safety issues. thelancet.com/journals/landi… Jakob Urs Mühlematter, Christian Bluethgen, Unispital_USZ funded by Swiss National Science Foundation covered by NZZ

Thinking the future of essential medicines World Health Organization (WHO). Great thoughts with incredible talents and scientific superstars

Global competition between countries on the successful development of AI technologies has emerged over the past decade, with medicine at the forefront of interest. This study finds that China dominated in terms of absolute number of trials. Read more: nejm.ai/40AE2re

New study geographic representation of trials for AI med devices NEJM AI: 97% national. Approx half in China, followed by US & Japan nejm.ai/40AE2re. Funded by Swiss National Science Foundation Covered by Swiss National News SRF News Georg Halter w/ Thomas Frauenfelder srf.ch/news/schweiz/n…

Neujahr ist die Zeit für neue Regeln – jedes Jahr treten Hunderte davon in Kraft. Doch wer ist dafür verantwortlich, und wo wird am meisten vorgeschrieben? Ein Zürcher Forschungsteam hat dies untersucht. Von Daniel Gerny nzz.ch/schweiz/es-gib…

Happy to share our new perspective article in The Lancet Oncology highlighting shortages of #essential (and #curative) #cancer medicines thelancet.com/journals/lanon… Kudos to amazing co-authors Kristina Jenei Kerstin Noëlle Vokinger Surgery and Cancer University of Zurich LSE Health Policy Imperial College London

Viewpoint compares use and costs of GLP-1 receptor agonists for weight loss between the US and 3 other peer countries. ja.ma/3LnIfI2

Drug prices declined substantially after patent expiration across 8 high-income countries, from 30% to 80% during the 8 years after patent expiration. ja.ma/3yDG4NV Kerstin Noëlle Vokinger